STP & TIP ARE ESSENTIAL FOR HERPESVIRUS SAIMIRI ONCOGENICITY
STP & TIP ARE ESSENTIAL FOR HERPESVIRUS SAIMIRI ONCOGENICITY
批准号:
6453742
负责人:
Samuel Monroe DUBOISE
金额:
$11.11万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-05-01 至 2002-04-30
中文摘要
松鼠猴疱疹病毒C亚群488株的突变型
构建了STP-C488或Tip缺失的细胞。
在细胞培养中测试HVS突变体的转化潜力
在普通绒猴亲本“VS C亚群488株中
体外永生化普通绒猴T淋巴细胞,
白细胞介素-2非依赖性生长,但缺失突变体
野生型“VS产生了致命的
实验性感染后19至20天内的淋巴瘤
绒猴,而“VS ASTP-C488和“VS ATip是非致癌病毒
从绒猴的外周血中反复分离
感染变异病毒5个月以上
证明复制不需要STP-C488和头端,或
持久性,但每一个都是细胞培养转化所必需的
以及普通绒猴中的淋巴瘤诱导
SM,Guo,J,Czajak,S,Desrosiers,RC和Jung,JU STP和Tip是
疱疹病毒Saimiri的致瘤性J Virol 1998;
72:1308-1313
英文摘要
Mutant forms of herpesvirus saimiri (HVS) subgroup C strain 488
with deletions in either STP-C488 or Tip were constructed The
transforming potentials of the HVS mutants were tested in cell culture
and in common marmosets Parental "VS subgroup C strain 488
immortalized common marmoset T lymphocytes in vitro to
interleukin-2-independent growth, but neither of the deletion mutants
produced such growth transformation Wild-type "VS produced fatal
lymphoma within 19 to 20 days of experimental infection of common
marmosets, while "VS ASTP-C488 and "VS ATip were nononcogenic Virus
was repeatedly isolated from the peripheral blood of marmosets
infected with mutant virus for more than 5 months These results
demonstrate that STP-C488 and Tip are not required for replication or
persistence, but each is essential for transformation in cell culture
and for lymphoma induction in common marmosets PUBLICATIONS Duboise,
SM, Guo, J, Czajak, S, Desrosiers, RC and Jung, JU STP and Tip are
Essential for Herpesvirus Saimiri Oncogenicity J Virol 1998;
72:1308-1313
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Micro-and Nano-space Explorations of Health and Disease
-
批准号:7902315
-
项目类别:
-
资助金额:$19.93万
-
财政年份:2009
-
负责人:Samuel Monroe DUBOISE
-
依托单位:
Micro-and Nano-space Explorations of Health and Disease
-
批准号:8019562
-
项目类别:
-
资助金额:$26.53万
-
财政年份:2008
-
负责人:Samuel Monroe DUBOISE
-
依托单位:
Micro-and Nano-space Explorations of Health and Disease
-
批准号:7326207
-
项目类别:
-
资助金额:$27.0万
-
财政年份:2008
-
负责人:Samuel Monroe DUBOISE
-
依托单位:
Micro-and Nano-space Explorations of Health and Disease
-
批准号:8333622
-
项目类别:
-
资助金额:$11.25万
-
财政年份:2008
-
负责人:Samuel Monroe DUBOISE
-
依托单位:
Micro-and Nano-space Explorations of Health and Disease
-
批准号:8228155
-
项目类别:
-
资助金额:$26.22万
-
财政年份:2008
-
负责人:Samuel Monroe DUBOISE
-
依托单位:
Micro-and Nano-space Explorations of Health and Disease
-
批准号:7557887
-
项目类别:
-
资助金额:$26.8万
-
财政年份:2008
-
负责人:Samuel Monroe DUBOISE
-
依托单位:
Micro-and Nano-space Explorations of Health and Disease
-
批准号:7761692
-
项目类别:
-
资助金额:$26.8万
-
财政年份:2008
-
负责人:Samuel Monroe DUBOISE
-
依托单位:
MUTATATED LCK BINDING MOTIF FOR LYMPHOID CELL ACTIVATION BY HERPESVIRUS SAIMIRI
-
批准号:6591295
-
项目类别:
-
资助金额:$11.11万
-
财政年份:2002
-
负责人:Samuel Monroe DUBOISE
-
依托单位:
ROLE FOR HERPESVIRUS SAIMIRI ORF14 IN TRANSFORMATION & PERSISTENT INFECTION
-
批准号:6591291
-
项目类别:
-
资助金额:$11.11万
-
财政年份:2002
-
负责人:Samuel Monroe DUBOISE
-
依托单位:
STP & TIP ARE ESSENTIAL FOR HERPESVIRUS SAIMIRI ONCOGENICITY
-
批准号:6591296
-
项目类别:
-
资助金额:$11.11万
-
财政年份:2002
-
负责人:Samuel Monroe DUBOISE
-
依托单位:
ROLE FOR HERPESVIRUS SAIMIRI ORF14 IN TRANSFORMATION & PERSISTENT INFECTION
-
批准号:6453737
-
项目类别:
-
资助金额:$11.11万
-
财政年份:2001
-
负责人:Samuel Monroe DUBOISE
-
依托单位:
MURINE GAMMAHERPESVIRUS 68 GENE EXPRESSION AND FUNCTION
-
批准号:6225239
-
项目类别:
-
资助金额:$14.5万
-
财政年份:2001
-
负责人:Samuel Monroe DUBOISE
-
依托单位:
MUTATATED LCK BINDING MOTIF FOR LYMPHOID CELL ACTIVATION BY HERPESVIRUS SAIMIRI
-
批准号:6453741
-
项目类别:
-
资助金额:$11.11万
-
财政年份:2001
-
负责人:Samuel Monroe DUBOISE
-
依托单位:
MUTATATED LCK BINDING MOTIF FOR LYMPHOID CELL ACTIVATION BY HERPESVIRUS SAIMIRI
-
批准号:6116558
-
项目类别:
-
资助金额:$11.16万
-
财政年份:1999
-
负责人:Samuel Monroe DUBOISE
-
依托单位:
STP & TIP ARE ESSENTIAL FOR HERPESVIRUS SAIMIRI ONCOGENICITY
-
批准号:6116559
-
项目类别:
-
资助金额:$11.16万
-
财政年份:1999
-
负责人:Samuel Monroe DUBOISE
-
依托单位:
ROLE FOR HERPESVIRUS SAIMIRI ORF14 IN TRANSFORMATION & PERSISTENT INFECTION
-
批准号:6116554
-
项目类别:
-
资助金额:$11.16万
-
财政年份:1999
-
负责人:Samuel Monroe DUBOISE
-
依托单位:
海外基金